Archived news

Letter to NICE in response to the decision regarding Tofersen 

20 March 2024

The UK MND Clinical Studies Group has written to the National Institute for Health and Care Excellence (NICE), expressing concern over the decision to appraise the drug Tofersen through the Single Technology Appraisal route, and the implications this will have for people living with motor neuron disease in the UK.  You can read the letter here